nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—ADRB1—dilated cardiomyopathy	0.41	0.543	CbGaD
Nadolol—ADRB2—dilated cardiomyopathy	0.345	0.457	CbGaD
Nadolol—ABCB1—Lisinopril—dilated cardiomyopathy	0.0712	0.532	CbGbCtD
Nadolol—ABCB1—Spironolactone—dilated cardiomyopathy	0.0627	0.468	CbGbCtD
Nadolol—Pemphigoid—Furosemide—dilated cardiomyopathy	0.0102	0.142	CcSEcCtD
Nadolol—ADRB3—Adrenoceptors—ADRB1—dilated cardiomyopathy	0.00283	0.089	CbGpPWpGaD
Nadolol—Pancreatitis acute—Furosemide—dilated cardiomyopathy	0.00276	0.0385	CcSEcCtD
Nadolol—Atrioventricular block complete—Lisinopril—dilated cardiomyopathy	0.00274	0.0381	CcSEcCtD
Nadolol—Abdominal bloating—Furosemide—dilated cardiomyopathy	0.00268	0.0373	CcSEcCtD
Nadolol—ADRB3—Adrenoceptors—ADRB2—dilated cardiomyopathy	0.00229	0.0721	CbGpPWpGaD
Nadolol—Blood triglycerides increased—Furosemide—dilated cardiomyopathy	0.00195	0.0271	CcSEcCtD
Nadolol—Lethargy—Spironolactone—dilated cardiomyopathy	0.00174	0.0242	CcSEcCtD
Nadolol—Sleep disturbance—Lisinopril—dilated cardiomyopathy	0.00171	0.0238	CcSEcCtD
Nadolol—ADRB2—Adrenoceptors—ADRB1—dilated cardiomyopathy	0.00164	0.0517	CbGpPWpGaD
Nadolol—Gastritis—Spironolactone—dilated cardiomyopathy	0.00151	0.021	CcSEcCtD
Nadolol—ADRB1—Adrenoceptors—ADRB2—dilated cardiomyopathy	0.00136	0.0428	CbGpPWpGaD
Nadolol—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00136	0.0189	CcSEcCtD
Nadolol—Throat sore—Lisinopril—dilated cardiomyopathy	0.00133	0.0185	CcSEcCtD
Nadolol—Oropharyngeal discomfort—Lisinopril—dilated cardiomyopathy	0.00132	0.0183	CcSEcCtD
Nadolol—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00122	0.017	CcSEcCtD
Nadolol—Ventricular extrasystoles—Lisinopril—dilated cardiomyopathy	0.00106	0.0147	CcSEcCtD
Nadolol—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.00105	0.0146	CcSEcCtD
Nadolol—Alopecia—Spironolactone—dilated cardiomyopathy	0.00104	0.0145	CcSEcCtD
Nadolol—ADRB3—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.000999	0.0315	CbGpPWpGaD
Nadolol—Lethargy—Furosemide—dilated cardiomyopathy	0.000946	0.0132	CcSEcCtD
Nadolol—Fluid retention—Lisinopril—dilated cardiomyopathy	0.000909	0.0126	CcSEcCtD
Nadolol—Irritability—Furosemide—dilated cardiomyopathy	0.000884	0.0123	CcSEcCtD
Nadolol—Pirbuterol—ADRB1—dilated cardiomyopathy	0.000861	0.111	CrCbGaD
Nadolol—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.000852	0.0119	CcSEcCtD
Nadolol—ADRB3—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.00084	0.0265	CbGpPWpGaD
Nadolol—ADRB3—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.00081	0.0255	CbGpPWpGaD
Nadolol—Abdominal distension—Furosemide—dilated cardiomyopathy	0.000806	0.0112	CcSEcCtD
Nadolol—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.000803	0.0112	CcSEcCtD
Nadolol—Levobunolol—ADRB1—dilated cardiomyopathy	0.000767	0.0985	CrCbGaD
Nadolol—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.000763	0.0106	CcSEcCtD
Nadolol—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00075	0.0104	CcSEcCtD
Nadolol—Pirbuterol—ADRB2—dilated cardiomyopathy	0.000724	0.093	CrCbGaD
Nadolol—Diplopia—Lisinopril—dilated cardiomyopathy	0.000695	0.00967	CcSEcCtD
Nadolol—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00069	0.00959	CcSEcCtD
Nadolol—Sweating—Furosemide—dilated cardiomyopathy	0.000685	0.00952	CcSEcCtD
Nadolol—ADRB3—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.000681	0.0214	CbGpPWpGaD
Nadolol—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.000666	0.00927	CcSEcCtD
Nadolol—Irritability—Lisinopril—dilated cardiomyopathy	0.000664	0.00923	CcSEcCtD
Nadolol—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000662	0.0092	CcSEcCtD
Nadolol—Carteolol—ADRB1—dilated cardiomyopathy	0.000652	0.0838	CrCbGaD
Nadolol—Levobunolol—ADRB2—dilated cardiomyopathy	0.000645	0.0829	CrCbGaD
Nadolol—ADRB3—Calcium Regulation in the Cardiac Cell—RYR2—dilated cardiomyopathy	0.000633	0.0199	CbGpPWpGaD
Nadolol—Visual impairment—Furosemide—dilated cardiomyopathy	0.000618	0.00859	CcSEcCtD
Nadolol—ADRB3—Calcium Regulation in the Cardiac Cell—PLN—dilated cardiomyopathy	0.000615	0.0194	CbGpPWpGaD
Nadolol—Gastritis—Lisinopril—dilated cardiomyopathy	0.000615	0.00856	CcSEcCtD
Nadolol—Tinnitus—Furosemide—dilated cardiomyopathy	0.000598	0.00831	CcSEcCtD
Nadolol—Pruritus—Spironolactone—dilated cardiomyopathy	0.000592	0.00824	CcSEcCtD
Nadolol—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.000591	0.00822	CcSEcCtD
Nadolol—ADRB2—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.00058	0.0183	CbGpPWpGaD
Nadolol—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000573	0.00797	CcSEcCtD
Nadolol—Bupranolol—ADRB1—dilated cardiomyopathy	0.000555	0.0712	CrCbGaD
Nadolol—Dizziness—Spironolactone—dilated cardiomyopathy	0.000554	0.0077	CcSEcCtD
Nadolol—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.000553	0.0077	CcSEcCtD
Nadolol—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.00055	0.0173	CbGpPWpGaD
Nadolol—Flatulence—Furosemide—dilated cardiomyopathy	0.00055	0.00765	CcSEcCtD
Nadolol—Carteolol—ADRB2—dilated cardiomyopathy	0.000549	0.0705	CrCbGaD
Nadolol—Weight increased—Lisinopril—dilated cardiomyopathy	0.000547	0.00761	CcSEcCtD
Nadolol—Depression—Lisinopril—dilated cardiomyopathy	0.000534	0.00743	CcSEcCtD
Nadolol—Vomiting—Spironolactone—dilated cardiomyopathy	0.000532	0.0074	CcSEcCtD
Nadolol—Rash—Spironolactone—dilated cardiomyopathy	0.000528	0.00734	CcSEcCtD
Nadolol—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000527	0.00733	CcSEcCtD
Nadolol—Vision blurred—Furosemide—dilated cardiomyopathy	0.000526	0.00731	CcSEcCtD
Nadolol—Salbutamol—ADRB1—dilated cardiomyopathy	0.000521	0.067	CrCbGaD
Nadolol—Sweating—Lisinopril—dilated cardiomyopathy	0.000514	0.00714	CcSEcCtD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00051	0.0161	CbGpPWpGaD
Nadolol—Penbutolol—ADRB1—dilated cardiomyopathy	0.000507	0.0652	CrCbGaD
Nadolol—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.0005	0.00695	CcSEcCtD
Nadolol—Nausea—Spironolactone—dilated cardiomyopathy	0.000497	0.00692	CcSEcCtD
Nadolol—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00049	0.00681	CcSEcCtD
Nadolol—ADRB2—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.000488	0.0154	CbGpPWpGaD
Nadolol—ADRB1—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.000481	0.0151	CbGpPWpGaD
Nadolol—Hallucination—Lisinopril—dilated cardiomyopathy	0.000479	0.00666	CcSEcCtD
Nadolol—ADRB2—Arf6 signaling events—AGTR1—dilated cardiomyopathy	0.000473	0.0149	CbGpPWpGaD
Nadolol—Bupranolol—ADRB2—dilated cardiomyopathy	0.000466	0.0599	CrCbGaD
Nadolol—Dry mouth—Furosemide—dilated cardiomyopathy	0.000465	0.00646	CcSEcCtD
Nadolol—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000448	0.00624	CcSEcCtD
Nadolol—Shock—Furosemide—dilated cardiomyopathy	0.000448	0.00623	CcSEcCtD
Nadolol—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00044	0.00612	CcSEcCtD
Nadolol—Salbutamol—ADRB2—dilated cardiomyopathy	0.000439	0.0563	CrCbGaD
Nadolol—Anorexia—Furosemide—dilated cardiomyopathy	0.000434	0.00604	CcSEcCtD
Nadolol—Penbutolol—ADRB2—dilated cardiomyopathy	0.000427	0.0548	CrCbGaD
Nadolol—Hypotension—Furosemide—dilated cardiomyopathy	0.000426	0.00592	CcSEcCtD
Nadolol—Alopecia—Lisinopril—dilated cardiomyopathy	0.000425	0.00591	CcSEcCtD
Nadolol—Flatulence—Lisinopril—dilated cardiomyopathy	0.000413	0.00574	CcSEcCtD
Nadolol—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000409	0.00569	CcSEcCtD
Nadolol—ADRB1—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.000404	0.0127	CbGpPWpGaD
Nadolol—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000396	0.00551	CcSEcCtD
Nadolol—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000395	0.00549	CcSEcCtD
Nadolol—Fatigue—Furosemide—dilated cardiomyopathy	0.000393	0.00546	CcSEcCtD
Nadolol—Constipation—Furosemide—dilated cardiomyopathy	0.000389	0.00542	CcSEcCtD
Nadolol—Pain—Furosemide—dilated cardiomyopathy	0.000389	0.00542	CcSEcCtD
Nadolol—ADRB1—Calcium Regulation in the Cardiac Cell—RYR2—dilated cardiomyopathy	0.000375	0.0118	CbGpPWpGaD
Nadolol—Syncope—Lisinopril—dilated cardiomyopathy	0.000375	0.00522	CcSEcCtD
Nadolol—ADRB2—Arf6 trafficking events—AGTR1—dilated cardiomyopathy	0.000373	0.0118	CbGpPWpGaD
Nadolol—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000368	0.00512	CcSEcCtD
Nadolol—ADRB2—Calcium Regulation in the Cardiac Cell—RYR2—dilated cardiomyopathy	0.000367	0.0116	CbGpPWpGaD
Nadolol—Pindolol—ADRB1—dilated cardiomyopathy	0.000366	0.047	CrCbGaD
Nadolol—Cough—Lisinopril—dilated cardiomyopathy	0.000365	0.00508	CcSEcCtD
Nadolol—ADRB1—Calcium Regulation in the Cardiac Cell—PLN—dilated cardiomyopathy	0.000365	0.0115	CbGpPWpGaD
Nadolol—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00036	0.00501	CcSEcCtD
Nadolol—ADRB2—Calcium Regulation in the Cardiac Cell—PLN—dilated cardiomyopathy	0.000357	0.0113	CbGpPWpGaD
Nadolol—Chest pain—Lisinopril—dilated cardiomyopathy	0.000356	0.00496	CcSEcCtD
Nadolol—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000349	0.00485	CcSEcCtD
Nadolol—ADRB3—G alpha (s) signalling events—ADRB1—dilated cardiomyopathy	0.000347	0.0109	CbGpPWpGaD
Nadolol—ADRB2—Arf6 trafficking events—ITGB1—dilated cardiomyopathy	0.000342	0.0108	CbGpPWpGaD
Nadolol—Oedema—Lisinopril—dilated cardiomyopathy	0.000342	0.00475	CcSEcCtD
Nadolol—Shock—Lisinopril—dilated cardiomyopathy	0.000336	0.00468	CcSEcCtD
Nadolol—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00033	0.00459	CcSEcCtD
Nadolol—Asthenia—Furosemide—dilated cardiomyopathy	0.000327	0.00454	CcSEcCtD
Nadolol—Anorexia—Lisinopril—dilated cardiomyopathy	0.000326	0.00453	CcSEcCtD
Nadolol—Pruritus—Furosemide—dilated cardiomyopathy	0.000322	0.00448	CcSEcCtD
Nadolol—Hypotension—Lisinopril—dilated cardiomyopathy	0.000319	0.00444	CcSEcCtD
Nadolol—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000312	0.00433	CcSEcCtD
Nadolol—Insomnia—Lisinopril—dilated cardiomyopathy	0.000309	0.0043	CcSEcCtD
Nadolol—Pindolol—ADRB2—dilated cardiomyopathy	0.000308	0.0395	CrCbGaD
Nadolol—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000307	0.00427	CcSEcCtD
Nadolol—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000305	0.00424	CcSEcCtD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.000303	0.00954	CbGpPWpGaD
Nadolol—Dizziness—Furosemide—dilated cardiomyopathy	0.000301	0.00419	CcSEcCtD
Nadolol—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000301	0.00418	CcSEcCtD
Nadolol—ADRB3—Calcium Regulation in the Cardiac Cell—ADRB1—dilated cardiomyopathy	0.000299	0.00943	CbGpPWpGaD
Nadolol—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000297	0.00413	CcSEcCtD
Nadolol—ADRB2—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.000296	0.00933	CbGpPWpGaD
Nadolol—Fatigue—Lisinopril—dilated cardiomyopathy	0.000295	0.0041	CcSEcCtD
Nadolol—Pain—Lisinopril—dilated cardiomyopathy	0.000292	0.00406	CcSEcCtD
Nadolol—Constipation—Lisinopril—dilated cardiomyopathy	0.000292	0.00406	CcSEcCtD
Nadolol—Vomiting—Furosemide—dilated cardiomyopathy	0.00029	0.00403	CcSEcCtD
Nadolol—Rash—Furosemide—dilated cardiomyopathy	0.000287	0.00399	CcSEcCtD
Nadolol—Dermatitis—Furosemide—dilated cardiomyopathy	0.000287	0.00399	CcSEcCtD
Nadolol—ADRB3—G alpha (s) signalling events—ADRB2—dilated cardiomyopathy	0.000281	0.00885	CbGpPWpGaD
Nadolol—Nausea—Furosemide—dilated cardiomyopathy	0.00027	0.00376	CcSEcCtD
Nadolol—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00027	0.00376	CcSEcCtD
Nadolol—ADRB2—GPCRs, Other—CXCR3—dilated cardiomyopathy	0.000266	0.00838	CbGpPWpGaD
Nadolol—ADRB1—Endothelin Pathways—RAF1—dilated cardiomyopathy	0.000247	0.00779	CbGpPWpGaD
Nadolol—ADRB3—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.000247	0.00778	CbGpPWpGaD
Nadolol—Asthenia—Lisinopril—dilated cardiomyopathy	0.000245	0.00341	CcSEcCtD
Nadolol—ADRB3—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.000242	0.00764	CbGpPWpGaD
Nadolol—Pruritus—Lisinopril—dilated cardiomyopathy	0.000242	0.00336	CcSEcCtD
Nadolol—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000234	0.00325	CcSEcCtD
Nadolol—Dizziness—Lisinopril—dilated cardiomyopathy	0.000226	0.00314	CcSEcCtD
Nadolol—Vomiting—Lisinopril—dilated cardiomyopathy	0.000217	0.00302	CcSEcCtD
Nadolol—Rash—Lisinopril—dilated cardiomyopathy	0.000215	0.003	CcSEcCtD
Nadolol—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000215	0.00299	CcSEcCtD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000214	0.00675	CbGpPWpGaD
Nadolol—Nausea—Lisinopril—dilated cardiomyopathy	0.000203	0.00282	CcSEcCtD
Nadolol—ADRB2—G alpha (s) signalling events—ADRB1—dilated cardiomyopathy	0.000201	0.00634	CbGpPWpGaD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000199	0.00627	CbGpPWpGaD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000193	0.00608	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000184	0.00578	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000184	0.00578	CbGpPWpGaD
Nadolol—ADRB2—Calcium Regulation in the Cardiac Cell—ADRB1—dilated cardiomyopathy	0.000174	0.00547	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000171	0.00538	CbGpPWpGaD
Nadolol—ADRB1—G alpha (s) signalling events—ADRB2—dilated cardiomyopathy	0.000167	0.00525	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000165	0.00521	CbGpPWpGaD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000165	0.00519	CbGpPWpGaD
Nadolol—ADRB2—Arf6 signaling events—EGFR—dilated cardiomyopathy	0.000158	0.00499	CbGpPWpGaD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000156	0.00492	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000156	0.0049	CbGpPWpGaD
Nadolol—ADRB1—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.000147	0.00462	CbGpPWpGaD
Nadolol—ADRB1—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.000144	0.00453	CbGpPWpGaD
Nadolol—ADRB2—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.000143	0.00452	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000141	0.00445	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00014	0.0044	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00014	0.0044	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000134	0.00422	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000131	0.00413	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00013	0.00409	CbGpPWpGaD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000127	0.00401	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000126	0.00396	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000124	0.00392	CbGpPWpGaD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000118	0.00372	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000116	0.00364	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000112	0.00353	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.00011	0.00346	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000109	0.00343	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000109	0.00343	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000107	0.00339	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000107	0.00336	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000107	0.00336	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000102	0.00322	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000102	0.00321	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000101	0.00319	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	9.93e-05	0.00313	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	9.91e-05	0.00312	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	9.84e-05	0.0031	CbGpPWpGaD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	9.78e-05	0.00308	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	9.59e-05	0.00302	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	9.56e-05	0.00301	CbGpPWpGaD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	9.27e-05	0.00292	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	8.38e-05	0.00264	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	8.29e-05	0.00261	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	8.29e-05	0.00261	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	8.19e-05	0.00258	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CXCL2—dilated cardiomyopathy	8.11e-05	0.00256	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—AGTR2—dilated cardiomyopathy	8.11e-05	0.00256	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	7.95e-05	0.0025	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	7.9e-05	0.00249	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	7.9e-05	0.00249	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	7.71e-05	0.00243	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—AGT—dilated cardiomyopathy	7.56e-05	0.00238	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CXCR3—dilated cardiomyopathy	7.54e-05	0.00238	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	7.34e-05	0.00231	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—ADRB1—dilated cardiomyopathy	7.31e-05	0.0023	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—AGTR2—dilated cardiomyopathy	7.17e-05	0.00226	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CXCL2—dilated cardiomyopathy	7.17e-05	0.00226	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	7.11e-05	0.00224	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CXCR3—dilated cardiomyopathy	6.67e-05	0.0021	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—ADRB1—dilated cardiomyopathy	6.46e-05	0.00203	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	6.38e-05	0.00201	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	6.35e-05	0.002	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—AGTR1—dilated cardiomyopathy	6.24e-05	0.00197	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	6.18e-05	0.00195	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	6.18e-05	0.00195	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	6.07e-05	0.00191	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	6.05e-05	0.00191	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	5.89e-05	0.00186	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	5.77e-05	0.00182	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	5.76e-05	0.00182	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	5.75e-05	0.00181	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—AGTR1—dilated cardiomyopathy	5.51e-05	0.00174	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—ADRB2—dilated cardiomyopathy	5.23e-05	0.00165	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	5.04e-05	0.00159	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	4.86e-05	0.00153	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.77e-05	0.0015	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	4.76e-05	0.0015	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	4.69e-05	0.00148	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	4.69e-05	0.00148	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	4.59e-05	0.00144	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	4.59e-05	0.00144	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—AGT—dilated cardiomyopathy	4.49e-05	0.00141	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—RAC1—dilated cardiomyopathy	4.47e-05	0.00141	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—AGT—dilated cardiomyopathy	4.39e-05	0.00138	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	4.36e-05	0.00137	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—AGT—dilated cardiomyopathy	4.27e-05	0.00135	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	4.26e-05	0.00134	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	4.26e-05	0.00134	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	4.26e-05	0.00134	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.24e-05	0.00133	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.24e-05	0.00133	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	4.18e-05	0.00132	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	4.18e-05	0.00132	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCL2—dilated cardiomyopathy	4.16e-05	0.00131	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AGTR2—dilated cardiomyopathy	4.16e-05	0.00131	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	4.13e-05	0.0013	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—RAC1—dilated cardiomyopathy	4.06e-05	0.00128	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	3.96e-05	0.00125	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.94e-05	0.00124	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	3.93e-05	0.00124	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—AGT—dilated cardiomyopathy	3.88e-05	0.00122	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCR3—dilated cardiomyopathy	3.87e-05	0.00122	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.81e-05	0.0012	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—ADRB1—dilated cardiomyopathy	3.75e-05	0.00118	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	3.6e-05	0.00114	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	3.55e-05	0.00112	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	3.53e-05	0.00111	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	3.42e-05	0.00108	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	3.27e-05	0.00103	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.26e-05	0.00103	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AGTR1—dilated cardiomyopathy	3.2e-05	0.00101	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	3.16e-05	0.000995	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	3.11e-05	0.000978	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.09e-05	0.000974	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PSEN2—dilated cardiomyopathy	2.83e-05	0.000892	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PSEN2—dilated cardiomyopathy	2.77e-05	0.000873	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.69e-05	0.000848	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.66e-05	0.000837	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	2.65e-05	0.000836	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	2.6e-05	0.000818	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AGT—dilated cardiomyopathy	2.54e-05	0.000799	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.51e-05	0.000792	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.51e-05	0.000792	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AGT—dilated cardiomyopathy	2.48e-05	0.000782	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.46e-05	0.000775	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.46e-05	0.000775	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—RAC1—dilated cardiomyopathy	2.41e-05	0.00076	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—RAC1—dilated cardiomyopathy	2.4e-05	0.000756	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—RAC1—dilated cardiomyopathy	2.36e-05	0.000743	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.34e-05	0.000736	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AGT—dilated cardiomyopathy	2.3e-05	0.000726	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AGT—dilated cardiomyopathy	2.29e-05	0.000722	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.29e-05	0.00072	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AGT—dilated cardiomyopathy	2.25e-05	0.00071	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.21e-05	0.000698	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	2.16e-05	0.000682	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	2.06e-05	0.00065	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.93e-05	0.000609	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.89e-05	0.000596	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.85e-05	0.000582	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.83e-05	0.000578	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.6e-05	0.000504	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—RAF1—dilated cardiomyopathy	1.59e-05	0.000501	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.58e-05	0.000497	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.56e-05	0.000493	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.54e-05	0.000486	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RAC1—dilated cardiomyopathy	1.42e-05	0.000449	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RAC1—dilated cardiomyopathy	1.39e-05	0.000439	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AGT—dilated cardiomyopathy	1.36e-05	0.000429	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AGT—dilated cardiomyopathy	1.33e-05	0.000419	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.25e-05	0.000395	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.1e-05	0.000345	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EGFR—dilated cardiomyopathy	1.09e-05	0.000344	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.07e-05	0.000338	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	9.65e-06	0.000304	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RAF1—dilated cardiomyopathy	9.44e-06	0.000297	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CD36—dilated cardiomyopathy	9.39e-06	0.000296	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RAF1—dilated cardiomyopathy	9.24e-06	0.000291	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AGT—dilated cardiomyopathy	8.46e-06	0.000267	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EGFR—dilated cardiomyopathy	6.48e-06	0.000204	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EGFR—dilated cardiomyopathy	6.33e-06	0.0002	CbGpPWpGaD
